Catalog No.
DHJ41001
Expression system
Mammalian Cells
Species reactivity
Human
Host species
Human
Isotype
IgG1-kappa
Clonality
Monoclonal
Target
LNIR, NECTIN4, PRR4 receptor-related protein 4, Nectin cell adhesion molecule 4, Ig superfamily receptor LNIR, Nectin-4, PVRL4
Concentration
1 mg/ml
Endotoxin level
Please contact with the lab for this information.
Purity
>95% as determined by SDS-PAGE.
Purification
Protein A/G purified from cell culture supernatant.
Accession
Q96NY8
Applications
Research Grade Biosimilar
Form
Liquid
Storage buffer
0.01M PBS, pH 7.4.
Stability and Storage
Use a manual defrost freezer and avoid repeated freeze-thaw cycles. Store at 4°C short term (1-2 weeks). Store at -20°C 12 months. Store at -80°C long term.
Alternative Names
AGS-22CE, AGS-22M, AGS-22M6E, unconjugated : AGS-22C3 or AGSM6, CAS: 1346452-25-2
Clone ID
Enfortumab
Pivotal Trial of Enfortumab Vedotin in Urothelial Carcinoma After Platinum and Anti-Programmed Death 1/Programmed Death Ligand 1 Therapy, PMID: 31356140
Enfortumab vedotin to treat urothelial carcinoma, PMID: 32406880
Enfortumab Vedotin Antibody-Drug Conjugate Targeting Nectin-4 Is a Highly Potent Therapeutic Agent in Multiple Preclinical Cancer Models, PMID: 27013195
Clinical Overview of Enfortumab Vedotin in the Management of Locally Advanced or Metastatic Urothelial Carcinoma, PMID: 31823332
Enfortumab Vedotin in urothelial cancer, PMID: 33447264
Enfortumab Vedotin-ejfv: A First-in-Class Anti-Nectin-4 Antibody-Drug Conjugate for the Management of Urothelial Carcinoma, PMID: 32945172
EV-101: A Phase I Study of Single-Agent Enfortumab Vedotin in Patients With Nectin-4-Positive Solid Tumors, Including Metastatic Urothelial Carcinoma, PMID: 32031899
Enfortumab Vedotin, a fully human monoclonal antibody against Nectin 4 conjugated to monomethyl auristatin E for metastatic urothelial Carcinoma, PMID: 31526130
A phase I study of enfortumab vedotin in Japanese patients with locally advanced or metastatic urothelial carcinoma, PMID: 31444589
FDA Approval Summary: Enfortumab Vedotin for Locally Advanced or Metastatic Urothelial Carcinoma, PMID: 32962979
Antibodies to watch in 2020, PMID: 31847708
Enfortumab vedotin shows promise in solid tumours, PMID: 32066546
Enfortumab Vedotin Checks Urothelial Cancer, PMID: 31519705
Enfortumab vedotin - next game-changer in urothelial cancer, PMID: 33325754
Flexural Exanthema From Enfortumab Vedotin, PMID: 32542157
The biology and rationale of targeting nectin-4 in urothelial carcinoma, PMID: 33239713
Management of metastatic bladder cancer, PMID: 31030123
Clinicopathologic characterization of enfortumab vedotin-associated cutaneous toxicity in patients with urothelial carcinoma, PMID: 33301805
Enfortumab Vedotin, PMID: 33630480
Emerging Treatment Options for the Treatment of Metastatic Urothelial Cancer: Therapeutic Potential of Enfortumab Vedotin, PMID: 32982431
Antibodies to watch in 2019, PMID: 30516432
The emerging role of antibody-drug conjugates in urothelial carcinoma, PMID: 32552213
Targeting Nectin-4 in Bladder Cancer, PMID: 28634245
A rare presentation of enfortumab vedotin-induced toxic epidermal necrolysis, PMID: 33319007
Antibody-Drug Conjugates in Urothelial Carcinomas, PMID: 32008109
Enfortumab vedotin is safe and effective, PMID: 34031573
Enfortumab Vedotin in Previously Treated Advanced Urothelial Carcinoma, PMID: 33577729
Cutaneous toxicity associated with enfortumab vedotin treatment of metastatic urothelial carcinoma, PMID: 30865407
Enfortumab vedotin for cisplatin-ineligible urothelial cancer, PMID: 33991513
Enfortumab Vedotin in Advanced Urothelial Carcinoma, PMID: 34192440
Enfortumab Vedotin in Advanced Urothelial Carcinoma. Reply, PMID: 34192441
Enfortumab vedotin after PD-1 or PD-L1 inhibitors in cisplatin-ineligible patients with advanced urothelial carcinoma (EV‑201): a multicentre, single-arm, phase 2 trial, PMID: 33991512
Benefit with enfortumab vedotin confirmed, PMID: 33649567
Profile of Enfortumab Vedotin in the Treatment of Urothelial Carcinoma: The Evidence to Date, PMID: 33603337
Expression of Nectin-4 and PD-L1 in Upper Tract Urothelial Carcinoma, PMID: 32751328
Advancements in Therapy for Bladder Cancer: Enfortumab Vedotin, PMID: 33604101
Targeted Molecular Therapeutics for Bladder Cancer-A New Option beyond the Mixed Fortunes of Immune Checkpoint Inhibitors?, PMID: 33019653
Re: Enfortumab Vedotin in Previously Treated Advanced Urothelial Carcinoma, PMID: 33895011
Severe eczematoid and lichenoid eruption with full-thickness epidermal necrosis developing from metastatic urothelial cancer treated with enfortumab vedotin, PMID: 32860247
Enfortumab Vedotin: Nursing Perspectives on the Management of Adverse Events in Patients With Locally Advanced or Metastatic Urothelial Carcinoma, PMID: 33739346
New and topics: enfortumab vedotin mechanisms of response and resistance in urothelial cancer - What do we understand so far?, PMID: 34148797
Case Report: Enfortumab Vedotin for Metastatic Urothelial Carcinoma: A Case Series on the Clinical and Histopathologic Spectrum of Adverse Cutaneous Reactions From Fatal Stevens-Johnson Syndrome/Toxic Epidermal Necrolysis to Dermal Hypersensitivity Reaction, PMID: 33747934
Current Systemic Treatment Options in Metastatic Urothelial Carcinoma after Progression on Checkpoint Inhibition Therapy-A Systemic Review Combined with Single-Group Meta-Analysis of Three Studies Testing Enfortumab Vedotin, PMID: 34206980
Benefit of nectin-4 targeting with enfortumab vedotin confirmed, PMID: 33692500
Cutaneous reactions with enfortumab vedotin: A case series and review of the literature, PMID: 34235241
Antibody-Drug Conjugates in Bladder Cancer, PMID: 30112436
Emerging biomarkers in urothelial carcinoma: Challenges and opportunities, PMID: 32920502
Antibody-drug conjugates for the treatment of urothelial carcinoma, PMID: 32589063
Updates in the management and future landscape of urothelial carcinoma, PMID: 33143526
The Evolution of Antibody-Drug Conjugates: A Positive Inflexion Point, PMID: 32223669